|
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Ga-DOTANOC PET/CT confirmed somatostatin receptor (SR) expression in hypervascularized liver lesions suggestive of neuroendocrine tumor that was later diagnosed as hepatocellular carcinoma (HCC).
|
30672751 |
2019 |
|
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In this review, we will summarize the available data on treatment of primary liver cancer with somatostatin analogues and analyze the current knowledge of somatostatin receptor expression in hepatocellular carcinoma and its possible clinical impact.
|
31569719 |
2019 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The aim of this retrospective cohort study was to investigate the effects of somatostatin on patients with MA after LT. MATERIAL AND METHODS Twenty-eight patients with liver cirrhosis or hepatocellular carcinoma who underwent LT complicated by MA postoperatively were included.
|
30598518 |
2019 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Hence, somatostatin receptor-directed strategies, sorafenib, and imatinib have revolutioned the management of neuroendocrine tumours (NET), hepatocellular carcinoma (HCC), and gastrointestinal stromal tumours (GIST), respectively, and are now used as first-line treatment in many patients affected by these tumours.
|
28723416 |
2018 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We therefore studied the effect of somatostatin octapeptide (octreotide) on the invasion and metastasis of HCC.
|
29990987 |
2018 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We aimed to evaluate the impact of somatostatin postoperative infusion on the incidence of ascites following hepatectomy by laparotomy for HCC in patients with underlying liver disease.
|
30139340 |
2018 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Somatostatin receptors in resected hepatocellular carcinoma: status and correlation with markers of poor prognosis.
|
27391928 |
2017 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The goal of this study is to investigate alteration in SSTR2 by the treatment of SSTR agonist octreotide (OCT) in hepatocellular carcinoma (HCC) and the resulting consequence.
|
19590186 |
2009 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Somatostatin receptor in human hepatocellular carcinomas: biological, patient and tumor characteristics.
|
18292657 |
2008 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Somatostatin receptor subtype 2-mediated scintigraphy and localization using (99m)Tc-HYNIC-Tyr(3)-octreotide in human hepatocellular carcinoma-bearing nude mice.
|
15991301 |
2005 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The efficacy of a targeted cytotoxic hybrid somatostatin analogue AN-238 and of its superactive radical 2-pyrrolinodoxorubicin (AN-201) to induce apoptosis of HepG2 and Hep3B human hepatoma cell lines were studied.
|
15664249 |
2005 |
|
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We, therefore, examined the production of somatostatin and cortistatin, the expression and distribution of somatostatin receptors (sst) in HepG2 human hepatocellular carcinoma cells, and the possible antiproliferative effect of octreotide on these cells.
|
15094227 |
2004 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Despite the widespread clinical use of somatostatin analogues in HCC, little is known about the expression of each of the five SSTRs in these tumors.
|
15246216 |
2004 |
|
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
As the somatostatin analog octreotide suppresses pituitary GH secretion and circulating IGF-1 levels, we examined its effects on human hepatoma (hep G2) cells which selectively express IGFBP-1.
|
1385103 |
1992 |